Cellular senescence risk score
1 paper1 finding
- In silico1
Effects
1Immunotherapy response rate
upin silico1
1 study
Immunotherapy response rate
upin silico1
Cellular senescence risk score improves immunotherapy response rate in silico.
“Tumour immune dysfunction and exclusion (TIDE) score and tumour mutation burden (TMB) score were better in the low-risk group, with advantages in terms of prognostic and immunotherapy response rate.”
In silicoin low-risk cellular senescence group
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP1 Dec 2025
Latest
1 in 12 monthsJournal of the College of Physicians and Surgeons--Pakistan
Development of a Cellular Senescence-Related Risk Model as a Prognostic Biomarker and Immunotherapy Response in Lung Squamous Cell Carcinoma
Computational studyBiomarkers